CTRI/2022/09/045375尚未招募2 期
A randomized, double blind, placebo controlled, comparative study to evaluate the safety and anti-aging efficacy of orally administered herbal extract formulations in elderly healthy individuals - AAHT01
Pharmanza Herbal0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients above 60 years of age belonging to either gender (males/females)
- •2.Fasting plasma glucose < 126 mg/dl, 2-hr glucose between 140 - 199 mg/dl
- •3.Patients willing to follow all trial procedures.
排除标准
- •Patients suffering from systemic illness necessitating long term drug treatment rheumatoid arthritis psychoneuroendocrinal disorders
- •Patients having any cardiovascular disease
- •Patients with diabetes mellitus HbA1c >6.5 FBS >126 mg/dl and PPBS > 200 mgdl
- •Patients with the concurrent hepatic disorder (defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >2 times upper normal limit, total bilirubin alkaline phosphates (ALP) >2 times the upper normal limit
- •Renal disorder is defined as S Creatinine > 3 mgdl
- •Patients with pulmonary dysfunction bronchial asthma and chronic obstructive pulmonary disease COPD
- •Inflammatory bowel disease
- •Severe dementia
- •Severe infection
- •Non-ambulatory patients or any other condition that may jeopardize the study
- •Subjects who are currently alcoholics and/or use psychoactive substances patients who have completed participation in any other clinical trial during the past 6 months
- •Subjects who have a history of allergy hypersensitivity or intolerance to investigational product
- •Subjects who have a history or evidence of active infection or febrile illness within 7 days prior to the screening assessment and subjects who have a history of any other clinically significant disease or disorder that, in the opinion of the principal investigator, may place the subject at risk due to participation in the study, or may influence the results of the study or the subject ability to complete the study
研究者
相似试验
Unknown
不适用
sing N-acetylcysteine as therapeutic drug for COVID-19 patients.CTRI/2020/06/026194Index Medical College and research centre Indore100
进行中（未招募）
1 期
A double-blind, placebo controlled, randomized, comparative, mono-centre trial to assess the effects on the androgen metabolism and its effects on biochemical parameters, mood, fat, muscle and bone of continuous supplementation with dehydroepiandrosterone in women using a monophasic contraception containing drospirenone and ethinylestradiol - AMUSABiochemical disturbances (androgens, lipids, bone markers, endocrine) and mood disturbances caused by the use of Oral Contraception (OC).EUCTR2007-003788-28-BEPantarhei Bioscience B.V.99
进行中（未招募）
1 期
A double-blind, placebo controlled, randomized, comparative, mono-centre trial to assess the impact of a monthly administration of 50.000 IU of Vitamin D during 6 months on Vitamin D level in healthy young adult volunteers. - D-plusEUCTR2010-022454-17-BEniversity of Liège- Dpt de Médecine Générale
已完成
2 期
Effects of concomitant treatment with an androgen on androgen metabolism, biochemical parameters, mood, fat, muscle and bone in women using an oral contraceptioISRCTN06414473Pantarhei Bioscience BV (Netherlands)100
进行中（未招募）
1 期
A double-blind, placebo controlled, randomised, comparative 2-way crossover study to determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on sexual arousability and the vascular component of the sexual arousal response during self-induced erotic fantasy and visual sexual stimulation in women using oral contraception (150 mcg levonorgestrel and 30 mcg ethinylestradiol or 3 mg drospirenone and 30 mcg ethinylestradiol) - ARC studyEUCTR2007-000013-10-NLPantarhei Bioscience B.V.82